Metabolomics profiling reveals differences in proliferation between tumorigenic and non-tumorigenic Madin-Darby canine kidney (MDCK) cells.
Cell proliferation
Choline metabolism
IDO
MAT
MDCK cells
S-adenosylmethionine
Targeted metabolomics
Tryptophan metabolism
Untargeted metabolomics
Journal
PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425
Informations de publication
Date de publication:
2023
2023
Historique:
received:
08
02
2023
accepted:
20
08
2023
medline:
26
9
2023
pubmed:
25
9
2023
entrez:
25
9
2023
Statut:
epublish
Résumé
Madin-Darby canine kidney (MDCK) cells are a cellular matrix in the production of influenza vaccines. The proliferation rate of MDCK cells is one of the critical factors that determine the vaccine production cycle. It is yet to be determined if there is a correlation between cell proliferation and alterations in metabolic levels. This study aimed to explore the metabolic differences between MDCK cells with varying proliferative capabilities through the use of both untargeted and targeted metabolomics. To investigate the metabolic discrepancies between adherent cell groups (MDCK-M60 and MDCK-CL23) and suspension cell groups (MDCK-XF04 and MDCK-XF06), untargeted and targeted metabolomics were used. Utilizing RT-qPCR analysis, the mRNA expressions of key metabolites enzymes were identified. An untargeted metabolomics study demonstrated the presence of 81 metabolites between MDCK-M60 and MDCK-CL23 cells, which were mainly affected by six pathways. An analysis of MDCK-XF04 and MDCK-XF06 cells revealed a total of 113 potential metabolites, the majority of which were impacted by ten pathways. Targeted metabolomics revealed a decrease in the levels of choline, tryptophan, and tyrosine in MDCK-CL23 cells, which was in accordance with the results of untargeted metabolomics. Additionally, MDCK-XF06 cells experienced a decrease in 5'-methylthioadenosine and tryptophan, while S-adenosylhomocysteine, kynurenine, 11Z-eicosenoic acid, 3-phosphoglycerate, glucose 6-phosphate, and phosphoenolpyruvic acid concentrations were increased. The mRNA levels of MAT1A, MAT2B, IDO1, and IDO2 in the two cell groups were all increased, suggesting that S-adenosylmethionine and tryptophan may have a significant role in cell metabolism. This research examines the effect of metabolite fluctuations on cell proliferation, thus offering a potential way to improve the rate of MDCK cell growth.
Sections du résumé
Background
Madin-Darby canine kidney (MDCK) cells are a cellular matrix in the production of influenza vaccines. The proliferation rate of MDCK cells is one of the critical factors that determine the vaccine production cycle. It is yet to be determined if there is a correlation between cell proliferation and alterations in metabolic levels. This study aimed to explore the metabolic differences between MDCK cells with varying proliferative capabilities through the use of both untargeted and targeted metabolomics.
Methods
To investigate the metabolic discrepancies between adherent cell groups (MDCK-M60 and MDCK-CL23) and suspension cell groups (MDCK-XF04 and MDCK-XF06), untargeted and targeted metabolomics were used. Utilizing RT-qPCR analysis, the mRNA expressions of key metabolites enzymes were identified.
Results
An untargeted metabolomics study demonstrated the presence of 81 metabolites between MDCK-M60 and MDCK-CL23 cells, which were mainly affected by six pathways. An analysis of MDCK-XF04 and MDCK-XF06 cells revealed a total of 113 potential metabolites, the majority of which were impacted by ten pathways. Targeted metabolomics revealed a decrease in the levels of choline, tryptophan, and tyrosine in MDCK-CL23 cells, which was in accordance with the results of untargeted metabolomics. Additionally, MDCK-XF06 cells experienced a decrease in 5'-methylthioadenosine and tryptophan, while S-adenosylhomocysteine, kynurenine, 11Z-eicosenoic acid, 3-phosphoglycerate, glucose 6-phosphate, and phosphoenolpyruvic acid concentrations were increased. The mRNA levels of MAT1A, MAT2B, IDO1, and IDO2 in the two cell groups were all increased, suggesting that S-adenosylmethionine and tryptophan may have a significant role in cell metabolism.
Conclusions
This research examines the effect of metabolite fluctuations on cell proliferation, thus offering a potential way to improve the rate of MDCK cell growth.
Identifiants
pubmed: 37744241
doi: 10.7717/peerj.16077
pii: 16077
pmc: PMC10517658
doi:
Substances chimiques
Tryptophan
8DUH1N11BX
5'-methylthioadenosine
634Z2VK3UQ
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16077Informations de copyright
©2023 Sun et al.
Déclaration de conflit d'intérêts
Jiayou Zhang, Kai Duan & Xuanxuan Nian are employees of Wuhan Institute of Biological Products Co., Ltd. Xiaoming Yang is the chairman of China National Biotech Group Company Limited. The authors declare there are no competing interests.
Références
Vaccine. 2013 Jan 21;31(5):850-6
pubmed: 23123018
Int J Tryptophan Res. 2019 Jun 19;12:1178646919852996
pubmed: 31258331
iScience. 2021 Jan 26;24(2):102090
pubmed: 33615198
Eur J Nutr. 2019 Apr;58(3):931-945
pubmed: 30298207
Ecotoxicol Environ Saf. 2022 Mar 1;232:113244
pubmed: 35093817
Expert Rev Vaccines. 2018 Jun;17(6):525-545
pubmed: 29939085
Crit Rev Biochem Mol Biol. 2013 Jan-Feb;48(1):20-38
pubmed: 23350810
J Physiol Pharmacol. 2015 Dec;66(6):779-91
pubmed: 26769827
Trends Biochem Sci. 2014 Aug;39(8):347-54
pubmed: 25037503
Biologicals. 2022 Oct;80:35-42
pubmed: 36114098
Comp Med. 2011 Jun;61(3):243-50
pubmed: 21819694
J Cell Physiol. 2018 Feb;233(2):736-747
pubmed: 28471487
Vaccine. 2010 Feb 3;28(5):1285-93
pubmed: 19944150
Front Immunol. 2022 Apr 13;13:886225
pubmed: 35493480
OMICS. 2013 Oct;17(10):495-501
pubmed: 23988149
Int J Biol Macromol. 2018 May;111:1255-1263
pubmed: 29366883
Dig Dis Sci. 2011 Apr;56(4):1007-19
pubmed: 20848206
Chemosphere. 2020 Sep;255:126865
pubmed: 32402870
Vaccines (Basel). 2022 May 01;10(5):
pubmed: 35632470
Cell. 2014 Dec 18;159(7):1591-602
pubmed: 25525877
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Dec 1;1102-1103:143-151
pubmed: 30391728
J Tissue Eng Regen Med. 2021 Mar;15(3):256-268
pubmed: 33462987
Biologicals. 2020 Nov;68:112-121
pubmed: 32928630
Vaccines (Basel). 2022 Jun 25;10(7):
pubmed: 35891184
J Neurochem. 2004 Jun;89(5):1252-9
pubmed: 15147518
Biochem Biophys Res Commun. 2021 Oct 1;572:178-184
pubmed: 34375927
J Hepatol. 2023 Mar;78(3):627-642
pubmed: 36462680
Front Endocrinol (Lausanne). 2020 Jun 09;11:365
pubmed: 32582032
Int J Mol Sci. 2022 Jan 12;23(2):
pubmed: 35054973
J Proteome Res. 2011 Sep 2;10(9):4165-76
pubmed: 21744784
World J Gastroenterol. 2019 Aug 21;25(31):4300-4319
pubmed: 31496615
Nat Rev Drug Discov. 2019 May;18(5):379-401
pubmed: 30760888
Int J Mol Sci. 2020 Jan 31;21(3):
pubmed: 32023913
Biotechnol Lett. 2016 Jun;38(6):941-8
pubmed: 26945752
Brain Res Dev Brain Res. 1999 Mar 12;113(1-2):13-20
pubmed: 10064869
Vaccine. 2014 Nov 12;32(48):6583-90
pubmed: 24975811
J Nutr Biochem. 1990 Jul;1(7):332-49
pubmed: 15539223
Oncotarget. 2016 May 31;7(22):32329-40
pubmed: 27058624
Front Endocrinol (Lausanne). 2021 Nov 15;12:791174
pubmed: 34867831
Nutr Today. 2007;42(4):181-186
pubmed: 18716669
Science. 2017 Jul 28;357(6349):
pubmed: 28751584
Anim Sci J. 2019 Sep;90(9):1278-1286
pubmed: 31293025
Biol Rev Camb Philos Soc. 2015 Aug;90(3):927-63
pubmed: 25243985